Their efficacy has to be tested in animal models of AD, which exhibits some degree of chronic inflammation generated by the pathological deposits such as beta-amyloid or tau, or in a “pure” animal model of chronic neuroinflammation such as the IL-1β or IL-6 overexpressing mouse (Ebrahimi and Schluesener, 2012; Millington et al., 2014). This evidence concerns the gene MAPT and Alzheimer disease.